{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:23:37Z","timestamp":1793053417408,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Colorado Department of Health Care Policy & Financing"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40273-023-01335-x","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T14:07:19Z","timestamp":1700575639000},"page":"319-328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid"],"prefix":"10.1007","volume":"42","author":[{"given":"Antal","family":"Zemplenyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"DiStefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth C.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"Mendola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Brett","family":"McQueen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"1335_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2019.107502","volume":"40","author":"C-C Ma","year":"2020","unstructured":"Ma C-C, Wang Z-L, Xu T, He Z-Y, Wei Y-Q. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol Adv. 2020;40: 107502. https:\/\/doi.org\/10.1016\/j.biotechadv.2019.107502.","journal-title":"Biotechnol Adv"},{"key":"1335_CR2","unstructured":"FDA. Approved cellular and gene therapy products. [Online]. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products. Accessed 1 Jun 2023."},{"issue":"1","key":"1335_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.drudis.2021.09.001","volume":"27","author":"CM Young","year":"2022","unstructured":"Young CM, Quinn C, Trusheim MR. Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues. Drug Discov Today. 2022;27(1):17\u201330. https:\/\/doi.org\/10.1016\/j.drudis.2021.09.001.","journal-title":"Drug Discov Today"},{"key":"1335_CR4","unstructured":"CVS Health. Latest look at projected gene therapies and approval timelines. 2022. [Online]. https:\/\/payorsolutions.cvshealth.com\/sites\/default\/files\/q2-2022-look-projected-gene-therapies-approval-timelines.pdf. Accessed 18 May 2023."},{"key":"1335_CR5","doi-asserted-by":"publisher","unstructured":"Baghdadi R. Medicaid best price. 2017. https:\/\/doi.org\/10.1377\/hpb20171008.000173.","DOI":"10.1377\/hpb20171008.000173"},{"key":"1335_CR6","unstructured":"Centers for Medicare & Medicaid Services. February 2023 Medicaid & CHIP enrollment data highlights. [Online]. https:\/\/www.medicaid.gov\/medicaid\/program-information\/medicaid-and-chip-enrollment-data\/report-highlights\/index.html#:~:text=93%2C373%2C794%20individuals%20were%20enrolled%20in,individuals%20were%20enrolled%20in%20Medicaid. Accessed 12 Jun 2023."},{"issue":"6","key":"1335_CR7","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.jval.2019.01.012","volume":"22","author":"SD Pearson","year":"2019","unstructured":"Pearson SD, Ollendorf DA, Chapman RH. New cost-effectiveness methods to determine value-based prices for potential cures: what are the options? Value Health. 2019;22(6):656\u201360. https:\/\/doi.org\/10.1016\/j.jval.2019.01.012.","journal-title":"Value Health"},{"issue":"9","key":"1335_CR8","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jval.2020.04.1833","volume":"23","author":"RMT ten Ham","year":"2020","unstructured":"ten Ham RMT, Klungel OH, Leufkens HGM, Frederix GWJ. A review of methodological considerations for economic evaluations of gene therapies and their application in literature. Value Health. 2020;23(9):1268\u201380. https:\/\/doi.org\/10.1016\/j.jval.2020.04.1833.","journal-title":"Value Health"},{"issue":"1","key":"1335_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/ajmg.c.32037","volume":"193","author":"LP Garrison","year":"2023","unstructured":"Garrison LP, Lo AW, Finkel RS, Deverka PA. A review of economic issues for <scp>gene-targeted<\/scp> therapies: Value, affordability, and access. Am J Med Genet C Semin Med Genet. 2023;193(1):64\u201376. https:\/\/doi.org\/10.1002\/ajmg.c.32037.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"1335_CR10","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12913-023-09494-5","volume":"23","author":"M Drummond","year":"2023","unstructured":"Drummond M, et al. How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? BMC Health Serv Res. 2023;23(1):484. https:\/\/doi.org\/10.1186\/s12913-023-09494-5.","journal-title":"BMC Health Serv Res"},{"key":"1335_CR11","unstructured":"IPG Health. Evolving outcomes-based agreements with cell & gene therapies. [Online]. https:\/\/ipghealth.com\/news\/evolving-outcomes-based-agreements-with-cell-gene-therapies. Accessed 18 May 2023."},{"key":"1335_CR12","unstructured":"NEWDIGS. Designing financial solutions to ensure affordable access to cures An overview of the MIT FoCUS project. 2018. [Online]. https:\/\/newdigs.tuftsmedicalcenter.org\/wp-content\/uploads\/2018\/11\/NEWDIGS-FoCUS-Frameworks-20180823.pdf. Accessed 18 May 2023."},{"key":"1335_CR13","unstructured":"U.S Food & Drug Administration. Zynteglo. [Online]. https:\/\/www.fda.gov\/vaccines-blood-biologics\/zynteglo. Accessed 18 May 2023."},{"key":"1335_CR14","unstructured":"U.S. Food & Drug Administration. Hemgenix. [Online]. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/hemgenix. Accessed 18 May 2023."},{"key":"1335_CR15","unstructured":"Biomarin. BioMarin\u2019s gene therapy for adults with severe hemophilia A, ROCTAVIANTM (valoctocogene roxaparvovec), assessed to provide substantial cost savings per patient in a preliminary independent report. [Online]. https:\/\/investors.biomarin.com\/2022-09-15-BioMarins-Gene-Therapy-for-Adults-with-Severe-Hemophilia-A,-ROCTAVIAN-TM-valoctocogene-roxaparvovec-,-Assessed-to-Provide-Substantial-Cost-Savings-Per-Patient-in-a-Preliminary-Independent-Report. Accessed 18 May 2023."},{"key":"1335_CR16","unstructured":"Biomarin. BioMarin provides update on FDA review of ROCTAVIANTM (Valoctocogene Roxaparvovec) gene therapy for adults with severe hemophilia A. [Online]. https:\/\/investors.biomarin.com\/2023-03-06-BioMarin-Provides-Update-on-FDA-Review-of-ROCTAVIAN-TM-Valoctocogene-Roxaparvovec-Gene-Therapy-for-Adults-with-Severe-Hemophilia-A\/. Accessed 18 May 2023."},{"key":"1335_CR17","unstructured":"Tufts Medical Center. CEA registry. 2023. [Online]. https:\/\/cear.tuftsmedicalcenter.org\/. Accessed 18 May 2023."},{"key":"1335_CR18","unstructured":"Institute of Clinical and Economic Review. Institute of Clinical and Economic Review Assessments. [Online]. https:\/\/icer.org\/explore-our-research\/assessments\/. Accessed 18 May 2023."},{"issue":"3","key":"1335_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.18553\/jmcp.2021.27.3.316","volume":"27","author":"SE Croteau","year":"2021","unstructured":"Croteau SE, et al. Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis. J Manag Care Spec Pharm. 2021;27(3):316\u201326. https:\/\/doi.org\/10.18553\/jmcp.2021.27.3.316.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"1335_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/13696998.2021.1891088","volume":"24","author":"N Li","year":"2021","unstructured":"Li N, et al. Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. J Med Econ. 2021;24(1):363\u201372. https:\/\/doi.org\/10.1080\/13696998.2021.1891088.","journal-title":"J Med Econ"},{"issue":"3","key":"1335_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/17474086.2020.1716726","volume":"13","author":"EC Rodriguez-Merchan","year":"2020","unstructured":"Rodriguez-Merchan EC. The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality. Expert Rev Hematol. 2020;13(3):269\u201374. https:\/\/doi.org\/10.1080\/17474086.2020.1716726.","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"1335_CR22","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/bloodadvances.2020003424","volume":"5","author":"TW Buckner","year":"2021","unstructured":"Buckner TW, et al. Health care resource utilization and cost burden of hemophilia B in the United States. Blood Adv. 2021;5(7):1954\u201362. https:\/\/doi.org\/10.1182\/bloodadvances.2020003424.","journal-title":"Blood Adv"},{"key":"1335_CR23","unstructured":"U.S. Bureau of Labor Statistics. Consumer Price Index, Calendar Year Historical, 2018-2022. [Online]. https:\/\/www.bls.gov\/regions\/southwest\/data\/consumerpriceindexcyhistorical_southwest_table.htm. Accessed 18 May 2023."},{"key":"1335_CR24","unstructured":"Rind D et al. Valoctocogene roxaparvovec and emicizumab for hemophilia a: effectiveness and value; final report. 2020. [Online]. https:\/\/icer-review.org\/material\/hemophilia-a-update-final-evidence-report\/. Accessed 15 Nov 2022."},{"key":"1335_CR25","unstructured":"Tice J et al. Gene therapy for hemophilia b and an update on gene therapy for hemophilia A: effectiveness and value evidence report prepared for. 2022. [Online]. https:\/\/icer.org\/assessment\/hemophilia-a-and-b-2022\/. Accessed 12 Dec 2022."},{"issue":"2","key":"1335_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/03007995.2022.2133492","volume":"39","author":"J Shah","year":"2023","unstructured":"Shah J, Kim H, Sivamurthy K, Monahan PE, Fries M. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B. Curr Med Res Opin. 2023;39(2):227\u201337. https:\/\/doi.org\/10.1080\/03007995.2022.2133492.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"1335_CR27","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40273-022-01234-7","volume":"41","author":"SP Gavan","year":"2023","unstructured":"Gavan SP, Wright SJ, Thistlethwaite F, Payne K. Capturing the impact of constraints on the cost-effectiveness of cell and gene therapies: a systematic review. Pharmacoeconomics. 2023;41(6):675\u201392. https:\/\/doi.org\/10.1007\/s40273-022-01234-7.","journal-title":"Pharmacoeconomics"},{"key":"1335_CR28","unstructured":"Department of Health and Human Services. HHS secretary responds to the president\u2019s executive order on drug prices. Press Release. [Online]. https:\/\/www.hhs.gov\/about\/news\/2023\/02\/14\/hhs-secretary-responds-to-the-presidents-executive-order-on-drug-prices.html. Accessed 25 Jun 2023."},{"key":"1335_CR29","unstructured":"Optum Rx. RoctavianTM (valoctocogene roxaparvovec-rvox)\u2014New orphan drug approval. 2023. [Online]. https:\/\/professionals.optumrx.com\/content\/dam\/optum3\/professional-optumrx\/news\/rxnews\/drug-approvals\/drugapproval_roctavian_2023-0629.pdf. Accessed 29 Oct 2023."},{"key":"1335_CR30","unstructured":"Biomarin. BioMarin announces stable and durable annualized bleed control for ROCTAVIANTM in largest phase 3 gene therapy study in adults with severe hemophilia a; 134-participant study met all primary and secondary efficacy endpoints at 3-year analysis. 2023. [Online]. https:\/\/investors.biomarin.com\/2023-01-08-BioMarin-Announces-Stable-and-Durable-Annualized-Bleed-Control-for-ROCTAVIAN-TM-in-Largest-Phase-3-Gene-Therapy-Study-in-Adults-with-Severe-Hemophilia-A-134-Participant-Study-Met-All-Primary-and-Secondary-Efficacy-Endpoints-at-3-Year-Analysis. Accessed 29 Oct 2023."},{"key":"1335_CR31","unstructured":"Reuters. Australia\u2019s CSL prices hemophilia gene therapy at $3.5 million. [Online]. https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/fda-approves-csls-gene-therapy-hemophilia-2022-11-22\/. Accessed 12 Dec 2022."},{"key":"1335_CR32","unstructured":"MDsave Incorporated. IV therapy infusion (1-3 hours). [Online]. https:\/\/www.mdsave.com\/procedures\/iv-therapy-infusion-1-3-hours\/d581ffcf. Accessed 15 Nov 2022."},{"issue":"14","key":"1335_CR33","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/bloodadvances.2018021345","volume":"2","author":"N Machin","year":"2018","unstructured":"Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Adv. 2018;2(14):1792\u20138. https:\/\/doi.org\/10.1182\/bloodadvances.2018021345.","journal-title":"Blood Adv"},{"issue":"3","key":"1335_CR34","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jth.15182","volume":"19","author":"S Hassan","year":"2021","unstructured":"Hassan S, et al. Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001\u20132018. J Thromb Haemost. 2021;19(3):645\u201353. https:\/\/doi.org\/10.1111\/jth.15182.","journal-title":"J Thromb Haemost"},{"key":"1335_CR35","unstructured":"Centers for Disease Control and Prevention. Underlying cause of death, 1999-2020 request. [Online]. https:\/\/wonder.cdc.gov\/controller\/datarequest\/D76. Accessed 14 Nov 2022."},{"issue":"5","key":"1335_CR36","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/13696998.2020.1721508","volume":"23","author":"K Cook","year":"2020","unstructured":"Cook K, Forbes SP, Adamski K, Ma JJ, Chawla A, Garrison LP. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A. J Med Econ. 2020;23(5):501\u201312. https:\/\/doi.org\/10.1080\/13696998.2020.1721508.","journal-title":"J Med Econ"},{"issue":"18","key":"1335_CR37","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1182\/blood.2021010864","volume":"138","author":"NS Bolous","year":"2021","unstructured":"Bolous NS, et al. The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. Blood. 2021;138(18):1677\u201390. https:\/\/doi.org\/10.1182\/blood.2021010864.","journal-title":"Blood"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01335-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-023-01335-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01335-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T11:08:10Z","timestamp":1707736090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-023-01335-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1335"],"URL":"https:\/\/doi.org\/10.1007\/s40273-023-01335-x","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]},"assertion":[{"value":"2 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of Colorado is funded by the Department of Health Care Policy & Financing for the assessment of value-based contracts. Dr. Zemplenyi authored this manuscript during his Fulbright Visiting Scholarship at the University of Colorado Anschutz Medical Campus.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Leonard is affiliated with the Colorado Department of Health Care Policy & Financing. The authors have disclosed no conflicts of interest concerning the research, authorship, or publication of this article. None of the authors are affiliated with or hold financial interests in the manufacturers of the gene therapies investigated in this study. The views expressed in this article represent the opinions of the authors and do not necessarily reflect those of their respective employers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"All data analyzed during this work are from the Colorado Department of Health Care Policy & Financing. The data are not publicly available. The model used during this work was developed by the University of Colorado under a contract with the Colorado Department of Health Care Policy & Financing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The study was declared\u00a0exempt\u00a0by the Colorado Multiple Institutional Review Board (no. 23-1401).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"AZ, BM, MD, KA, and KN contributed to the study conception and design. Material preparation, data collection and analysis were performed by Garth Wright, NM, and AZ. The first draft of the manuscript was written by AZ and BM and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}